Envestnet Asset Management Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,452,283 shares of the biopharmaceutical company’s stock after selling 54,929 shares during the quarter. Envestnet Asset Management Inc. owned about 0.20% of Gilead Sciences worth $168,251,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of the business. CarsonAllaria Wealth Management Ltd. increased its stake in shares of Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 238 shares during the period. Palisade Asset Management LLC acquired a new position in shares of Gilead Sciences during the first quarter worth about $29,000. Sachetta LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $30,000. Financial Connections Group Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth about $34,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $36,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 36,847 shares of company stock valued at $3,002,940. Insiders own 0.16% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Report on Gilead Sciences
Gilead Sciences Stock Performance
Shares of GILD stock opened at $82.81 on Monday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The company has a 50 day moving average price of $75.48 and a 200 day moving average price of $70.84. The firm has a market capitalization of $103.10 billion, a price-to-earnings ratio of 230.03, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.72%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- What Are Trending Stocks? Trending Stocks Explained
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- P/E Ratio Calculation: How to Assess Stocks
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.